Decorative petal
Product Finder
Product Finder
Press Releases

Lupin launches Sildenafil Tablets USP

Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Lupin’s Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, is the generic version of Pfizer Inc’s Viagra® Tablets, 25 mg, 50 mg, and 100 mg.  Sildenafil Tablets are a phosphodiesterase-5 (PDE5) inhibitor and are indicated for the treatment of erectile dysfunction (ED).

Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg had an annual salesof approximately USD 216 million in the U.S. (IQVIA MAT July 2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rdlargest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal/  

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Arvind Bothra Head Investor Relations / Corporate Communications Ph: +9122 6640 8237 Email: arvindbothra@lupin.com

*Safe Harbor Statement

Viagra® is a registered trademark of Pfizer Inc.

Product Finder